Aniracetam

Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone), also known by the code Ro 13-5057, is a pyrrolidinone-type nootropic and one of the earliest and most studied racetams after piracetam. Unlike the water-soluble piracetam, aniracetam is fat-soluble, a property that shapes its absorption and its rapid metabolism to compounds such as N-anisoyl-GABA. It is classified pharmacologically as an ampakine, a positive allosteric modulator of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors, the receptors that carry most fast excitatory signaling in the brain ^[4].

Developed by Hoffmann-La Roche, aniracetam has been used clinically, chiefly in Europe and Japan, for behavioral and psychological symptoms of dementia and for cognitive impairment following stroke and in Alzheimer's disease ^[1]. Its research literature describes cognition-enhancing effects across numerous rodent models of impaired attention, memory, mood, and anxiety, and it has been studied specifically for reversing learning and memory deficits caused by prenatal ethanol exposure by restoring synaptic AMPA receptor function ^[1][2][3]. As a canonical AMPA receptor potentiator it appears throughout the literature alongside newer agents developed for cognitive deficits, depression, and Parkinson's disease ^[4][5].

Regulatory status varies; aniracetam is a prescription or licensed medicine in several countries but is not approved by the US Food and Drug Administration, where it is sold as an unregulated nootropic supplement. It is available as a powder or in capsules, is frequently paired with a choline source to support the cholinergic system it draws on, and is regarded as generally well tolerated in the nootropic community ^[1].

Aniracetam has held up well in trials at up to 1500 mg a day. Europe treats it as a prescription drug (Draganon, Ampamet), while in the US it lives in a grey area; not FDA-approved, but sold everywhere anyway. Nothing points to liver, heart, or nerve toxicity. The most common gripe is a headache, and that's usually your brain running low on choline, so pair it with 300 mg alpha-GPC or 250 mg CDP-choline and it tends to clear up; you might also get mild stomach upset or some edginess at high doses. No serious drug interactions are on record, though it's wise to be careful alongside other glutamate-active compounds. Steer clear if you react badly to racetams, and skip it during pregnancy or breastfeeding.

Aniracetam was developed by the pharmaceutical company Hoffmann-La Roche in the 1970s as a fat-soluble member of the racetam family, following the original racetam piracetam. Unlike the water-soluble parent, its lipophilic structure was intended to cross into the brain more readily. It came to be marketed in parts of Europe and in Japan, under names such as Draganon and Sarpul, for cognitive symptoms including those following stroke and in dementia. Pharmacologically it was later characterized as one of the first ampakines, a positive allosteric modulator of AMPA-type glutamate receptors.

Aniracetam is one of the more respected members of the racetam family, valued by users for a combination of cognitive support and a reported calming, anxiolytic quality that many find distinctive among nootropics. Its mechanism as an ampakine, slowing the desensitization of the brain's main excitatory receptors, is well described and links it to enhanced long-term potentiation and to increased expression of the growth factor BDNF. Enthusiasts also note that its active metabolites are thought to contribute to its mood and anxiety effects. Balanced discussion acknowledges that robust, large-scale human trials are limited, that it is rapidly metabolized and short-acting, and that its status varies by country. It is generally seen as a well-regarded cognition enhancer with an appealing mechanistic rationale.